Barclays PLC Buys 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Barclays PLC lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 134.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 296,384 shares of the company's stock after acquiring an additional 169,756 shares during the period. Barclays PLC owned approximately 0.10% of Amneal Pharmaceuticals worth $2,466,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Rothschild Investment LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at $26,000. Gladius Capital Management LP bought a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $37,000. DekaBank Deutsche Girozentrale acquired a new position in Amneal Pharmaceuticals in the second quarter valued at approximately $42,000. nVerses Capital LLC acquired a new position in Amneal Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, Xponance Inc. bought a new position in Amneal Pharmaceuticals in the second quarter valued at approximately $65,000. 31.82% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 17.46% of the company's stock.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX remained flat at $7.85 on Thursday. 507,138 shares of the company were exchanged, compared to its average volume of 1,371,447. The stock's fifty day moving average price is $8.36 and its two-hundred day moving average price is $7.96. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -11.54 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target for the company in a research note on Friday, September 6th. Piper Sandler upped their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, October 2nd. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.